Researchers from Mayo Clinic compared results of colonoscopies following a positive result from Cologuard (unblinded) with colonoscopies performed by those who were not aware of the Cologuard result (blinded).
Here are four points:
1. Unblinded endoscopists found polyps or hemorrhagic lesions 83 percent of the time and precancerous polyps in 70 percent of patients.
2. Comparatively, blinded endoscopists found polyps or hemorrhagic lesions 68 percent of the time and precancerous polyps in 53 percent of patients.
3. Researchers also found unblinded endoscopists spent 46 percent more time and found twice as many polyps per colonoscopy.
4. Madison, Wis.-based Exact Sciences and Mayo Clinic co-developed Cologuard, which was the FDA approved in August 2014.
More articles on GI & endoscopy:
3 GI physicians in the news — May 20, 2016
Apollo Endosurgery launches telehealth platform for OBERA procedure patients: 4 things to know
Compulink to unveil GI EHR solution — 3 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.